San Carlos, CA, United States of America

Gordon A Vehar

This inventor holds 42 USPTO granted patents, primarily in Coagulation Therapy. Top assignees: Genentech, Inc., Genetech, Inc.. Active years: 1988-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gordon A Vehar. Retrieved from https://idiyas.com/inventor/gordon-a-vehar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 42

% Patents Active = 97.6

Average Co-Inventor Count = 3.0

ph-index = 13

Forward Citations = 760(Granted Patents)

Company Filing History:

Years Active: 1988-2007

Loading Chart...

Areas of Expertise:

Coagulation Disorders

Tissue Plasminogen Activators

Human Factor VIII

Recombinant Proteins

Myocardial Infarction

Tumor Treatment

Lipoprotein

Antibodies

Vectors

Cell Lines

DNA Encoding

Therapeutic Compositions

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. H0002181 - Human tPA production using vectors coding for DHFR protein (2007-02-05),

2. 7084251 - Methods and Deoxyribonucleic acid for the preparation of tissue factor protein (2006-08-01),

3. 7049131 - Methods and deoxyribonucleic acid for the preparation of tissue factor protein (2006-05-23),

4. 6994988 - Methods and deoxyribonucleic acid for the preparation of tissue factor protein (2006-02-07),

5. 6986894 - Methods for the treatment of coagulation disorders with lipoprotein associated coagulation inhibitor (LACI) (2006-01-17),

6. 6284247 - Human tissue plasminogen activators (2001-09-04),

7. 6274335 - Method of treatment using recombinant human tissue plasminogen activator (2001-08-14),

8. 6274142 - Methods of neutralizing coagulation with anti-tissue factor antibodies (2001-08-14),

9. 6261837 - Human tPA production using vectors coding for DHFR protein (2001-07-17),

10. 5869314 - Tissue plasminogen activators and derivatives thereof as produced by (1999-02-09),

11. 5849574 - Human tPA production using vectors coding for DHFR protein (1998-12-15),

12. 5830448 - Compositions and methods for the treatment of tumors (1998-11-03),

13. 5763253 - Methods of preparing tissue plasiminogen activator derivative composition (1998-06-09),

14. 5762921 - Composition and methods for the treatment of tumors (1998-06-09),

15. 5756093 - Tissue plasminogen activator variants (1998-05-26),

Title: The Innovative Journey of Gordon A Vehar

Introduction:

Gordon A Vehar, a talented inventor based in San Carlos, CA (US), has made significant contributions to the field of technology through his groundbreaking innovations and patents.

Latest Patents:

Gordon A Vehar's latest patents include cutting-edge technologies in the fields of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to invention.

Career Highlights:

With a career spanning over two decades, Gordon A Vehar has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing solutions that push the boundaries of what is possible. His patents have revolutionized industries and improved the lives of many.

Collaborations:

Throughout his career, Gordon A Vehar has collaborated with leading research institutions, universities, and innovative companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion:

In conclusion, Gordon A Vehar's passion for innovation, coupled with his dedication to creating meaningful change through his inventions, has solidified his reputation as a pioneering inventor in the technology sector. His continued commitment to pushing the boundaries of what is possible ensures that his legacy will endure for years to come.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]